Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
Gilead culls last MASH program, 2 cancer assets
The dropped oncology assets are a DGKα inhibitor and an MCL1 inhibitor, which join a Novo-partnered MASH program in the scrap heap.
Darren Incorvaia
Aug 8, 2025 11:50am
Gilead hands back one Arcus cancer candidate from $725M deal
Aug 7, 2025 6:35am
Galapagos builds island of cell therapies amid pipeline pruning
Jul 24, 2025 10:59am
China biotechs ‘reshaping’ US biopharma: Jefferies report
Jul 14, 2025 2:30pm
Merck wades deeper into HIV PrEP waters with pair of trials
Jul 14, 2025 1:12pm
Gilead blames low infection rates for ending 2 RSV trials
Jun 27, 2025 4:09am